Fig. 1 | Scientific Reports

Fig. 1

From: Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

Fig. 1

Changes in logMAR best-corrected visual acuity (BCVA) over 6 months. Mean logMAR BCVA values are shown for treatment-naïve and previously treated eyes at baseline and at 1, 2, 3, and 6 months following intravitreal faricimab treatment. Both groups demonstrated significant improvements in the BCVA from baseline at all post-treatment time points (p < 0.05 for all). At 6 months, BCVA improvement was significantly greater in the treatment-naïve group than in the previously treated group (p = 0.0109). Error bars indicate standard deviations. *indicates p < 0.05 versus baseline. Bracket with p = 0.0109 indicates a significant difference between groups at 6 months.

Back to article page